{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:15:02Z","timestamp":1783746902378,"version":"3.55.0"},"reference-count":11,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0267","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:11:37Z","timestamp":1783375897000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Enlargement of a Preexisting Pulmonary Nodule Mimicking Metastasis during Neoadjuvant Chemotherapy with Pembrolizumab for Triple-Negative Breast Cancer"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0873-2686","authenticated-orcid":false,"given":"Michiko","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Division of Breast Surgery, Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouko","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Chiba Cancer Center, Chiba, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 2024; 391: 1981\u201391.","DOI":"10.1056\/NEJMoa2409932"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541\u20133.","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143\u201352.","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lee B, Lim A, Lalvani A, et al. The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol 2008; 19: 2001\u20136.","DOI":"10.1093\/annonc\/mdn421"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Molinero L, Li Y, Chang C-W, et al. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer 2019; 7: 274.","DOI":"10.1186\/s40425-019-0740-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med 2019; 16: 655\u201370.","DOI":"10.20892\/j.issn.2095-3941.2019.0144"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nishino M, Sholl LM, Awad MM, et al. Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunol Res 2018; 6: 630\u20135.","DOI":"10.1158\/2326-6066.CIR-17-0715"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021; 39: 4073\u2013126.","DOI":"10.1200\/JCO.21.01440"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Zhong L, Altan M, Shannon VR, et al. Immune-related adverse events: pneumonitis. Adv Exp Med Biol 2020; 1244: 255\u201369.","DOI":"10.1007\/978-3-030-41008-7_13"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Makhlin I, Fox K. Oligometastatic breast cancer: is this a curable entity? A contemporary review of the literature. Curr Oncol Rep 2020; 22: 15.","DOI":"10.1007\/s11912-020-0867-2"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0267\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:08:56Z","timestamp":1783746536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0267\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0267","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0267"}}